[1]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980-982,986.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
　CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(7):980-982,986.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
点击复制

中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年7期
页码:
980-982,986
栏目:
综 述
出版日期:
2023-07-05

文章信息/Info

Title:
Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis
作者:
陈 曦1 ; 董凯旋1; 周 荣1; 于小勇2
(1.陕西中医药大学,陕西 咸阳 712046; 2.陕西省中医医院,陕西 西安 710003)
Author(s):
CHEN Xi; DONG Kaixuan; ZHOU Rong; YU Xiaoyong
(Shaanxi University of Chinese Medicine,Xianyang 712046,China)
关键词:
慢性肾脏病;  肾纤维化;  p38丝裂原活化蛋白激酶;  核因子κB;  氧化应激;  炎症反应
Keywords:
Chronic kidney disease;  Renal fibrosis;  p38MAPK;  NF-κB;  Oxidative stress;  Inflammatory response
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7369.2023.07.036
文献标志码:
A
摘要:
肾纤维化是一种慢性、动态且不可逆的病理改变,是慢性肾脏病进展的主要病理过程。p38丝裂原活化蛋白激酶/核因子κB(p38MAPK/NF-κB)信号参与炎症反应及氧化应激,在肾纤维化进展中发挥关键的调控作用。近年来中药通过靶向调控氧化应激及相关信号通路防治肾纤维化成为研究热点。研究表明单味中药及中药复方有效成分通过调控p38MAPK/NF-κB信号改善氧化应激损伤和炎症状态,发挥保护肾脏功能作用,且临床疗效较好。通过归纳中药调控p38MAPK/NF-κB信号通路干预肾纤维化机制的研究,为中医药防治本病提供参考。
Abstract:
Renal fibrosis is a chronic,dynamic and irreversible pathological change,which is the main pathological process of the progression of chronic kidney disease.p38 mitogen-activated protein kinase/nuclear factor-κB(p38MAPK/NF-κB)signaling is involved in inflammatory response and oxidative stress,and plays a key regulatory role in the progression of renal fibrosis.In recent years,traditional Chinese medicine becomed research hotspot in the prevention and treatment of renal fibrosis by targeted regulation of oxidative stress and related signaling pathways.Studies have shown that single traditional Chinese medicine and active ingredients of traditional Chinese medicine compound can improve oxidative stress injury and inflammatory state by regulating p38MAPK/NF-κB signaling play a role in protecting kidney function,and have significant clinical efficacy.Reviews the mechanism of traditional Chinese medicine regulating p38MAPK/NF-κB signaling pathway to intervene renal fibrosis,in order to provide a reference for prevention and treatment of renal fibrosis with traditional Chinese medicine.

参考文献/References:

[1] Li R,Guo Y,Zhang Y,et al.Salidroside ameliorates renal interstitial fibrosis by inhibiting the TLR4/NF-κB and MAPK signaling pathways[J].Int Journal Mol Sci,2019,20(5):457-462.
[2] 罗 珊,宋立群,马晓鹏,等.肾间质纤维化氧化应激相关信号通路与中医药研究进展[J].中医药学报,2020,48(12):79-84.
[3] 徐 薇,于小勇,毛加荣,等.慢性肾小管间质肾病辨证治疗思路与方法[J].陕西中医,2020,41(6):790-792.
[4] 杨 娜,任 丽.单味中医药抗肾纤维化机制研究进展[J].陕西中医,2009,30(2):248-250.
[5] 阮颖新,刘素雁,李春媚,等.p38MAPK通路参与肾间质纤维化的实验研究[J].临床泌尿外科杂志,2007,22(1):63-66.
[6] 霍振霞,王保兴.p38MAPK在氧化应激诱导肾间质纤维化中的研究进展[J].中华临床医师杂志:电子版,2016,10(7):1029-1032.
[7] Coulthard LR,White DE,Jones DL,et al.p38MAPK:Stress responses from molecular mechanisms to therapeutics[J].Trends Mol Med,2009,15(8):369-379.
[8] 杨晓萍,黄燕莉,王 杰,等.肾纤维化信号通路的中医药研究进展[J].世界中医药,2019,14(5):1084-1088.
[9] Lawrence T.The nuclear factor NF-κB pathway in inflammation[J].Cold Spring Harb Perspect Biol,2009,1(6):1651-1660.
[10] Mitchell S,Vargas J,Hoffmann A.Signaling via the NF-κB system[J].Wiley Interdiscip Rev Syst Biol Med,2016,8(3):227-241.
[11] Zhao Q,Wan Y,Wang C,et al.Regulatory mechanism of p38MAPK signaling pathway on renal tissue inflammation in chronic kidney disease and interventional effect of traditional Chinese medicine[J].China Journal of Chinese Materia Medica,2012,37(12):1700-1704.
[12] 门 凌,何日明,杨曙东,等.p38MAPK介导炎症在糖尿病肾病中作用研究进展[J].陕西医学杂志,2017,46(7):983-985.
[13] 王艺霖,黎崇裕,刘志龙.刘志龙教授治疗慢性肾衰竭经验介绍[J].光明中医,2022,37(2):217-220.
[14] 顾叶云,任现志.黄芪、水蛭有效组分及组分配伍对经脂多糖诱导增殖的大鼠肾小球系膜细胞p38MAPK/NF-κB信号通路的影响[J].中华中医药杂志,2021,36(11):6690-6694.
[15] 马思佳,赵明明,常美莹,等.黄芪治疗慢性肾炎中的网络药理学研究[J].世界中西医结合杂志,2020,15(8):1467-1472.
[16] Geng XQ,Ma A,He JZ,et al.Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways[J].Acta Pharmacol Sin,2020,41(5):670-677.
[17] 刘忠杰,孙卫卫,刘玉宁.蝉花菌丝对单侧输尿管结扎大鼠肾组织NF-κB、MCP-1表达的影响[J].中国中西医结合肾病杂志,2015,16(4):318-320.
[18] Qin T,Wang M,Zhang T,et al.Total C-21 steroidal glycosides from Baishouwu ameliorate hepatic and renal fibrosis by regulating IL-1β/MyD88 inflammation signaling[J].Front Pharmacol,2021,12(2):775-780.
[19] 原 景,杜 韩,万梅绪,等.丹参有效成分及丹参类制剂抗炎药理作用的研究进展[J].药物评价研究,2021,44(11):2322-2332.
[20] 徐文燕,管青聪,徐 芳.丹参提取物对系膜增生性肾小球肾炎大鼠TGF-β1/p38MAPK信号通路的影响研究[J].新中医,2020,52(2):5-9.
[21] 张少华,张彦芳,曹 萌,等.姜黄素对糖尿病肾病小鼠肾损伤及肾纤维化的影响及其机制[J].华中科技大学学报:医学版,2021,50(2):169-173.
[22] Wang Z,Chen Z,Li B,et al.Curcumin attenuates renal interstitial fibrosis of obstructive nephropathy by suppressing epithelial-mesenchymal transition through inhibition of the TLR4/NF-small Cyrillic-B and PI3K/Akt signalling pathways[J].Pharm Biol,2020,58(1):828-837.
[23] 任 桐,朱鹏宇,杨洪涛.水蛭素对单侧输尿管结扎大鼠肾间质纤维化的干预研究[J].四川中医,2019,37(2):64-68.
[24] 李芳梅,宋恩峰.泽兰对UUO大鼠肾脏核转录因子及血管内皮生长因子的影响[J].湖北中医学院学报,2010,12(3):3-6.
[25] 魏 升,钟光辉,曹晓丹,等.基于Sirt介导的NF-κB/NLRP3信号通路探讨黄芪甲苷及莪术醇对慢性肾功能衰竭大鼠的作用机制研究[J].新中医,2022,54(5):9-13.
[26] Zheng ZC,Zhu W,Lei L,et al.Wogonin ameliorates renal inflammation and fibrosis by inhibiting NF-κB and TGF-β1/Smad3 signaling pathways in diabetic nephropathy[J].Drug Des Devel Ther,2020,14(2):4135-4148.
[27] 孔祥静,丁国明,肖达平,等.黄芩总黄酮对慢性肾功能衰竭大鼠的肾保护作用及ROS/MAPK/NF-κB信号通路的影响[J].中国药师,2020,23(6):1042-1047.
[28] 张 凯,赵 龙.车前草水提取物对糖尿病肾病大鼠肾纤维化及p38MAPK/过氧PPAR-γ通路的影响[J].药品评价,2020,17(10):16-19.
[29] Quan Y,Park W,Jin J,et al.Sirtuin 3 activation by honokiol decreases unilateral ureteral obstruction-induced renal inflammation and fibrosis via regulation of mitochondrial dynamics and the renal NF-κB TGF-β1/Smad signaling pathway[J].Int Journal Mol Sci,2020,21(2):147-152.
[30] 杨 朔,胡俊华,王亚娟,等.雷公藤乙素对糖尿病肾病大鼠肾组织p-p38MAPK TNF-α及IL-1β表达的影响[J].中国中医药科技,2021,28(6):897-900.
[31] Wang J,Ge S,Wang Y,et al.Puerarin alleviates UUO-induced inflammation and fibrosis by regulating the NF-κB P65/STAT3 and TGFβ1/Smads signaling pathways[J].Drug Des Devel Ther,2021,15(2):3697-3708.
[32] Zhang S,Huang Q,Cai X,et al.Osthole ameliorates renal fibrosis in mice by suppressing fibroblast activation and epithelial-mesenchymal transition[J].Front Physiol,2018,9(1):1650.
[33] 金依依,周科挺,杨成成,等.蛇床子素抑制NF-κB和p38/MAPK改善糖尿病诱导的肾脏损伤[J].中国临床药理学与治疗学,2022,27(6):622-631.
[34] 杨少宁,周锦纹,陈丹倩,等.基于TGF-β1/p38MAPK通路探讨益血降浊汤对UUO大鼠肾纤维化的作用机制[J].云南中医中药杂志,2019,40(10):60-67.
[35] 江 茜,王 宏,王 蕾,等.尿毒康通过抑制p38/ERK MAPK通路改善UUO大鼠肾小管细胞上皮-间质转化[J].天津中医药,2021,38(1):103-108.
[36] 宋立群,周 波,贠 捷,等.真武汤调节肾间质纤维化大鼠NF-κB表达的研究[J].中国临床保健杂志,2014,17(1):68-70.
[37] 张进珍.二参益气补肾胶囊对慢性肾衰竭大鼠肾小管间质纤维化的保护及机制研究[J].中国中西医结合肾病杂志,2020,21(9):768-771.
[38] 陆海英,李志杰,舒 适,等.六味地黄丸基于SIRT6/NF-κB信号通路对糖尿病伴肝损伤的保护作用[J].中国实验方剂学杂志,2019,25(12):28-34.
[39] Mao ZM,Wan YG,Sun W,et al.Effects and mechanisms of Huangkui capsule ameliorating renal fibrosis in diabetic nephropathy rats via inhibiting oxidative stress and p38MAPK signaling pathway activity in kidney[J].China Journal of Chinese Materia Medica,2014,39(21):4110-4117.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(7):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(7):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(7):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(7):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(7):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(7):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[9]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
　ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(7):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
[10]王禹霖,刘梦超,郑冰洁,等.名中医张炳厚从瘀论治慢性肾脏病经验撷英[J].陕西中医,2023,(11):1602.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.026]
　WANG Yulin,LIU Mengchao,ZHENG Bingjie,et al.Experience of famous Chinese doctor Zhang Binghou treating chronic kidney disease by Yu[J].,2023,(7):1602.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.026]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82174366); 陕西省科技厅社发攻关一般项目(2017SF-298); 陕西中医药管理局科研项目(2021-GJ-LC022)
更新日期/Last Update: 2023-07-10